Advertisement

Topics

Deutsche Bank hebt Ziel für Gerresheimer auf 66 Euro - 'Hold'

06:58 EST 22 Jan 2018 | FinanzNachrichten
Related Biotechnology, Pharmaceutical and Healthcare News

Die Deutsche Bank hat das Kursziel für Gerresheimer vor Zahlen von 64 auf 66 Euro angehoben und die Einstufung auf "Hold" belassen. Anleger dürften bei Unternehmen aus dem europäischen Gesundheits...

Original Article: Deutsche Bank hebt Ziel für Gerresheimer auf 66 Euro - 'Hold'

NEXT ARTICLE

More From BioPortfolio on "Deutsche Bank hebt Ziel für Gerresheimer auf 66 Euro - 'Hold'"

Quick Links
Advanced Search | Login | Subscribe | RSS

Quick Search
Advertisement

 

News Quicklinks

Search Biotech, Medical and Healthcare News

Popular Biotech, Medical and Healthcare News

Biotech News by Article Type

BioPortfolio Bloggers

Publishing Your News on BioPortfolio

Recent Visitor News Searches

BioPortfolio Limited Social Media
Publish Content Agreements
Tools Help

HON Code certificate This site complies with the HONcode standard for trustworthy health information:
Verify here.

The information provided by BioPortfolio.com is not a substitute for professional medical advice, diagnosis or treatment. The BioPortfolio site is sponsored BioPortfolio Limited with offices at Stafford House, 10 Prince of Wales Road, Dorchester, DT1 1PW, England. If you are a legal copyright holder or a designated agent for such and you believe a post on this website falls outside the boundaries of “Fair Use” and legitimately infringes on your or your client's copyright we may be contacted concerning copyright matters here: Contact BioPortfolio.
All rights reserved. All other trademarks recognized. Copyright © 1997-2018 BioPortfolio Limited. Site developed by Alacrify Ltd.